Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AREC.LSE
- Price
- 38.00
- Stock movement up
- +- (%)
- Company name
- Arecor Therapeutics PLC
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.43B
- Ent value
- 1.44B
- Price/Sales
- 243.32
- Price/Book
- 282.54
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 25.98%
- 1 year return
- -70.43%
- 3 year return
- -54.37%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-15
DIVIDENDS
AREC.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 243.32 |
| Price to Book | 282.54 |
| EV to Sales | 243.79 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 37.76M |
| EPS (TTM) | -0.28 |
| FCF per share (TTM) | -0.21 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 5.90M |
| Gross profit (TTM) | 4.70M |
| Operating income (TTM) | -9.05M |
| Net income (TTM) | -8.67M |
| EPS (TTM) | -0.28 |
| EPS (1y forward) | -0.17 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 79.78% |
| Operating margin (TTM) | -153.55% |
| Profit margin (TTM) | -146.97% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.53M |
| Net receivables | 1.62M |
| Total current assets | 6.38M |
| Goodwill | 1.48M |
| Intangible assets | 1.74M |
| Property, plant and equipment | 0.00 |
| Total assets | 10.37M |
| Accounts payable | 2.27M |
| Short/Current long term debt | 280.00K |
| Total current liabilities | 4.66M |
| Total liabilities | 5.29M |
| Shareholder's equity | 5.08M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -5.58M |
| Capital expenditures (TTM) | 93.00K |
| Free cash flow (TTM) | -6.31M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -170.66% |
| Return on Assets | -83.60% |
| Return on Invested Capital | -167.01% |
| Cash Return on Invested Capital | -121.54% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 38.00 |
| Daily high | 38.67 |
| Daily low | 38.00 |
| Daily Volume | 14K |
| All-time high | 450.00 |
| 1y analyst estimate | 363.67 |
| Beta | -0.27 |
| EPS (TTM) | -0.28 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| AREC.LSE | S&P500 | |
| Current price drop from All-time high | -91.56% | -12.04% |
| Highest price drop | -91.56% | -56.47% |
| Date of highest drop | 14 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -47.47% | -11.07% |
| Avg time to new high | 195 days | 12 days |
| Max time to new high | 897 days | 1805 days |
COMPANY DETAILS
Marketcap
1.43B
Marketcap category
Small-cap
Description
Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications ion the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes; and specialty hospital products. In addition, the company is developing AT247, an ultra-rapid acting insulin, which is in Phase 1 for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product; and Medtronic plc to develop a novel thermostable insulin for implantable pump delivery. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Employees
50
Website
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found